<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Adenovirus (Ad)-based gene therapy represents a potentially viable strategy for treating <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The infectivity of serotype 5 adenovirus (Ad.5), routinely used as a transgene delivery vector, is dependent on Coxsackie-adenovirus receptors (CAR) </plain></SENT>
<SENT sid="2" pm="."><plain>CAR expression is downregulated in many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> thus preventing optimum therapeutic efficiency of Ad.5-based therapies </plain></SENT>
<SENT sid="3" pm="."><plain>To overcome the low CAR problem, a serotype chimerism approach was used to generate a recombinant Ad (Ad.5/3) that is capable of infecting <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells via Ad.3 receptors in a CAR-independent manner </plain></SENT>
<SENT sid="4" pm="."><plain>We evaluated the improved transgene delivery and efficacy of Ad.5/3 recombinant virus expressing <z:hpo ids='HP_0002861'>melanoma</z:hpo> differentiation associated gene-7/interleukin-24 (mda-7/IL-24), an effective wide-spectrum <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-selective therapeutic </plain></SENT>
<SENT sid="5" pm="."><plain>In low CAR human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells RKO, <z:mp ids='MP_0002169'>wild-type</z:mp> Ad.5 virus expressing mda-7/IL-24 (Ad.5-mda-7) failed to infect efficiently resulting in lack of expression of <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 or induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>However, a recombinant Ad.5/3 virus expressing mda-7/IL-24 (Ad.5/3-mda-7) efficiently infected RKO cells resulting in higher <z:chebi fb="14" ids="32506">MDA</z:chebi>-7/IL-24 expression and inhibition of cell growth both in vitro and in <z:mp ids='MP_0003815'>nude</z:mp> mice <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Addition of the novel Bcl-2 family pharmacological inhibitor Apogossypol derivative BI-97C1 (Sabutoclax) significantly augmented the efficacy of Ad.5/3-mda-7 </plain></SENT>
<SENT sid="8" pm="."><plain>A combination regimen of suboptimal doses of Ad.5/3-mda-7 and BI-97C1 profoundly enhanced cytotoxicity in RKO cells both in vitro and in vivo </plain></SENT>
<SENT sid="9" pm="."><plain>Considering the fact that Ad.5-mda-7 has demonstrated significant objective responses in a Phase I clinical trial for advanced <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, Ad.5/3-mda-7 alone or in combination with BI-97C1 would be predicted to exert significantly improved therapeutic efficacy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>